Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Novel PPARdelta agonists identified by Bayer researchers

Sep. 3, 2004

Oralin submitted for approval in Ecuador

Sep. 2, 2004

Neurocrine presents new melanocortin MC3/MC4 modulators and their use

Sep. 2, 2004

Novel series of MC4 receptor agonists highlighted at recent ACS meeting

Sep. 2, 2004

Preclinical evidence suggests a role for Flt3-ligand in the treatment of diabetes

Sep. 2, 2004

Merck scientists identify new cannabinoid CB1 modulators for obesity and other uses

Sep. 1, 2004

Novel DPP-IV inhibitors developed at Merck & Co.

Sep. 1, 2004

Thiophene-based PPARdelta agonist with high potency and selectivity

Sep. 1, 2004

Two series of antiobesity cannabinoid CB1 ligands designed at AstraZeneca

Aug. 31, 2004

Phase II proof-of-concept study successfully completed for icatibant in HAE

Aug. 31, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
Unmasking the X: EPAC2 shifts the fragile X landscape
BioWorld
Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...